Showing 1071-1080 of 5808 results for "".
A New Option for Estrogen Deficient Skin
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-new-option-for-estrogen-deficient-skin-/19587/Post-menopausal women often experience dryness, thinning, and atrophy of the skin as a result of estrogen deficiency, Diane Berson, MD says. She discusses a new cosmeceutical now available that helps to non-hormonally restore the natural function of estrogen deficient skin.SC: not just a dead layer
https://practicaldermatology.com/topics/general-topics/sc-not-just-a-dead-layer/19528/Take a deep look inside the stratum corneum (SC) and understand its role in overall skin health. Learn what metabolic processes are important to SC health and, in turn, what processes are affected by a suboptimal SC.NPF Services, Eskata Update, AAD Meeting Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-npf-services-eskata-update-aad-meeting-data/18326/The National Psoriasis Foundation is expanding its services to patients, with a special focus on teens affected by the Skin Disease. Widely anticipated by both physicians and patients, Eskata will be available for in-office use this spring. Aclaris CEO, Dr. Neal Walker addresses the launch, as wellPearls for Treating Skin Cancer
https://practicaldermatology.com/topics/general-topics/pearls-for-treating-skin-cancer/18446/When should you treat basal cell carcinomas with adjuvant therapies before excising? Why is the number two important to remember when treating squamous cell carcinoma? Is Merkel cell carcinoma on the rise? Gary Goldenberg, MD answers these questions and offers an update on the newest therapies and bRe-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumaA Change in Technology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/technology-2017/18513/From innovations in fillers to enhancements of energy-based devices, core physicians will find new ways to optimize outcomes in 2017, says Suneel Chilukuri, MD in this video memo.The Importance of Link Building for your Practice
https://practicaldermatology.com/topics/practice-management/the-importance-of-link-building-for-your-practice/18554/The link-building discussion is sometimes confusing, but link building is never a waste of time. They add value to content and build credibility of content. Links from quality sources promote content, boost traffic, and build visibility. This Ekwa.com Ekwa educational video explains why link-buildinCSF 2016 Highlights from the Founder
https://practicaldermatology.com/topics/skin-cancer-photoprotection/csf-2016-highlights-from-the-founder/18711/Cosmetic Surgery Forum Founder and Practical Dermatology® Chief Surgical Editor Joel Schlessinger, MD talks about CSF 2016. What sets the meeting apart? How has it evolved in 8 years? And what did he learn from this year's program? Find out.Lasers in Acne: Expanding the Options
https://practicaldermatology.com/topics/general-topics/lasers-in-acne-expanding-the-options/18745/By Abigail Waldman, MD and Seemal R. Desai, MDThe Nd-YAG (1064nm) laser can be used for acne—including cystic acne—and acne scarring. Dr. Waldman discusses the AAD's first-ever hands-on laser session and the role of the Nd-YAG laser in patient care.Risk In Your Portfolio
https://practicaldermatology.com/topics/practice-management/risk-in-your-portfolio/18588/Do you know your risk score? Physicians must understand their personal tolerance for risk as well as the level of risk in their current portfolios. If there is a mismatch, how do you rectify the disconnect. Bob Peelman, CFP, of OJM Group, explains. ABOUT THE AUTHOR